370 related articles for article (PubMed ID: 26464015)
1. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
Chung DJ; Pronschinske KB; Shyer JA; Sharma S; Leung S; Curran SA; Lesokhin AM; Devlin SM; Giralt SA; Young JW
Cancer Immunol Res; 2016 Jan; 4(1):61-71. PubMed ID: 26464015
[TBL] [Abstract][Full Text] [Related]
2. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
[TBL] [Abstract][Full Text] [Related]
3. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
Front Immunol; 2021; 12():618610. PubMed ID: 33717112
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
6. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.
Condomines M; Quittet P; Lu ZY; Nadal L; Latry P; Lopez E; Baudard M; Requirand G; Duperray C; Schved JF; Rossi JF; Tarte K; Klein B
J Immunol; 2006 Jun; 176(11):6631-9. PubMed ID: 16709821
[TBL] [Abstract][Full Text] [Related]
7. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
9. TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
Minnie SA; Waltner OG; Ensbey KS; Olver SD; Collinge AD; Sester DP; Schmidt CR; Legg SR; Takahashi S; Nemychenkov NS; Sekiguchi T; Driessens G; Zhang P; Koyama M; Spencer A; Holmberg LA; Furlan SN; Varelias A; Hill GR
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36512425
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
Derman BA; Zha Y; Zimmerman TM; Malloy R; Jakubowiak A; Bishop MR; Kline J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940591
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
13. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
14. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
15. Relapsed multiple myeloma: who benefits from salvage autografts?
Chow AW; Lee CH; Hiwase DK; To LB; Horvath N
Intern Med J; 2013 Feb; 43(2):156-61. PubMed ID: 22757772
[TBL] [Abstract][Full Text] [Related]
16. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
17. Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma.
Cohen AD; Lendvai N; Nataraj S; Imai N; Jungbluth AA; Tsakos I; Rahman A; Mei AH; Singh H; Zarychta K; Kim-Schulze S; Park A; Venhaus R; Alpaugh K; Gnjatic S; Cho HJ
Cancer Immunol Res; 2019 Apr; 7(4):658-669. PubMed ID: 30745365
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.
Arteche-López A; Kreutzman A; Alegre A; Sanz Martín P; Aguado B; González-Pardo M; Espiño M; Villar LM; García Belmonte D; de la Cámara R; Muñoz-Calleja C
Bone Marrow Transplant; 2017 Jun; 52(6):832-838. PubMed ID: 28368375
[TBL] [Abstract][Full Text] [Related]
19. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract][Full Text] [Related]
20. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
Chung DJ; Sharma S; Rangesa M; DeWolf S; Elhanati Y; Perica K; Young JW
Blood Adv; 2022 Mar; 6(5):1547-1558. PubMed ID: 35100339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
